

[Supplementary online-only material for Remington G, Rodriguez Y, Logan D, Williamson C, Treadaway K: Facilitating medication adherence in patients with multiple sclerosis. *Int J MS Care*. 2013;15:36–45.]

Additional References

Armstrong AW, Frangos JE, Kimball AB, Kvedar JC. Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. *Arch Dermatol*. 2009;145:1230–1236.

Brandes D, Bigley K, Hornstein W, et al. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. *Curr Med Res Opin*. 2007;23:1667–1672.

Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. *Leuk Res*. 2011;35:626–630.

Farrell K, Shen BJ, Mallon S, Penedo FJ, Antoni MH. Utility of the Millon Behavioral Medicine Diagnostic to predict medication adherence in patients diagnosed with heart failure. *J Clin Psychol Med Settings*. 2011;18:1–12.

Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. *J Neurosci Nurs*. 2003;35:163–170.

Fraser C, Margante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. *J Neurosci Nurs*. 2004;36:120–129.

Frohman E. Dr. Elliot Frohman on managing injection site reactions. *Inside MS*. 2005;62–63.

- Ingersall KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. *J Behav Med.* 2008;31:213–224.
- Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. *Neuropsychology.* 2010;24:573–580.
- Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. *Neurology.* 2003;61:1528–1532.
- Meletiche D, Kozma C, Bennett R, Al-Sabbagh A. Relationship between severe relapses and adherence to disease-modifying therapy in multiple sclerosis patients. *J Neurol.* 2008b;255(suppl 2):P826.
- Pyne JM, Fortney JC, Curran GM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. *Arch Intern Med.* 2011;171:23–31.
- Schwartz CE, Coulthard-Morris L, Zeng Q, Retzlaff P. Measuring self-efficacy in people with multiple sclerosis: a validation study. *Arch Phys Med Rehabil.* 1996;77:394–398.
- Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. *Clin Drug Investig.* 2010;30:89–100.